Kiniksa Pharmaceuticals International, plc Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
Kiniksa Pharmaceuticals International, plc (KNSA) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $684.00 thousand for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-04.
Discontinued › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2023-05-04
- Kiniksa Pharmaceuticals International, plc right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-03-31 was $684.00K.
- Kiniksa Pharmaceuticals International, plc right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-12-31 was $0.00, a 100.00% decline year-over-year.
- Kiniksa Pharmaceuticals International, plc right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2021-12-31 was $157.00K.
- Kiniksa Pharmaceuticals International, plc right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $2.88M, a 77.64% increase from fiscal 2021.
- Kiniksa Pharmaceuticals International, plc right-of-use asset obtained in exchange for operating lease liability for fiscal 2021 was $1.62M, a 73.19% decline from fiscal 2020.
- Kiniksa Pharmaceuticals International, plc right-of-use asset obtained in exchange for operating lease liability for fiscal 2020 was $6.04M.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2023-03-31 | $684.00K 10-Q · filed 2023-05-04 | $684.00K derived: sum of 2 quarters · filed 2023-05-04 | ||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $2.88M 10-K · filed 2023-03-02 | ||
| 2022-09-30 | $2.88M 10-Q · filed 2022-11-03 | |||
| 2021-12-31 | $157.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $1.62M 10-K · filed 2023-03-02 | ||
| 2021-09-30 | $1.46M 10-Q · filed 2022-11-03 | |||
| 2020-12-31 | $6.04M 10-K · filed 2023-03-02 |